Santhera Pharmaceuticals has partnered with Uniphar to distribute AGAMREE in the UAE, Saudi Arabia, Kuwait, Oman, and Bahrain for treating Duchenne muscular dystrophy in patients aged four and older. Sales will start on a named patient basis in Q1 2026, with broader availability expected later in the year pending market authorization and pricing agreement. Santhera will receive a portion of net sales as payment.

Read more at Nasdaq: Santhera Pharma Partners With Uniphar For AGAMREE Distribution In Gulf Region